Provident Financial Services, Inc.

PFS • Banks - Regional

$22.53

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL MUY FAVORABLEExcelenteConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$2.94B

Crecimiento

7.8%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 21.1%Crecimiento positivo de ingresos · 13.4%Flujo de caja libre positivo · 3.3Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 8.86

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$22.53

Change0.00%

Shares Out130.49M

Market Cap$2.94B

Enterprise Value$-574.84M

52W Range17.61 - 25.41

Beta0.78

P/E9.40

P/S2.18

P/B1.01

P/FCF6.93

EV/Sales-0.43

Price$22.53

Change0.00%

Shares Out130.49M

Market Cap$2.94B

Enterprise Value$-574.84M

52W Range17.61 - 25.41

Beta0.78

P/E9.40

P/S2.18

P/B1.01

P/FCF6.93

EV/Sales-0.43

EV/EBITDA-1.04

EV/FCF-1.35

Earnings Yield10.64%

FCF Yield14.43%

Dividend Yield3.20%

Gross Margin62.69%

Oper. Margin29.52%

Profit Margin21.06%

Debt/Eq0.89

Current Ratio0.00

Quick Ratio0.00

Revenue 5Y7.79%

FCF 5Y2.47%

Target$26.50

Target Upside17.62%

Target Median$26.50

Target Range26.00 - 27.00

Volume1.52M

Avg Volume1.03M

EPS Surprise0.06

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

85/100

Fortaleza financiera

Deuda, caja, estabilidad

33/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

89/100

Por qué este puntaje▼

Márgenes estables o en mejora · 21.1%Crecimiento positivo de ingresos · 13.4%Flujo de caja libre positivo · 3.3Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 8.86Nivel de deuda manejable · 0.89

Analyst view

Analyst sentiment and price target

PFS

Analyst sentiment

Based on 10 analyst votes · 2026-10-20

80/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-31

Bajo

$27.00

Promedio

$27.00

Mediana

$27.00

Alto

$27.00

Resumen de la compañía

IPO: 1/16/2003

Industria: Banks - Regional

P/B i: 1.01

Deuda / Patrimonio i: 0.89

Margen operativo: 29.52%

Margen neto: 21.06%

ROE i: -

ROIC: -

Salud financiera

Puntaje7 / 20

Deuda / Patrimonio: 0.89

Ratio corriente: 0.00

Ratio rápido: 0.00

Estado: Weak

Transacciones internas

Actividad reciente de ejecutivos e insiders

LISTA GEORGE

Transacción: 06/12/2026

VENTA

Cambio

-3,528

Precio

$23.41

Presentación

06/15/2026

Tipo

VENTA

Vitelli Annamaria

Transacción: 06/01/2026

OTRO

Cambio

Precio

Not reported

Presentación

06/05/2026

Tipo

OTRO

Flynn Brian

Transacción: 05/26/2026

COMPRA

Cambio

+4,012

Precio

Not reported

Presentación

05/28/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
LISTA GEORGE	VENTA	-3,528	$23.41	06/12/2026	06/15/2026
Vitelli Annamaria	OTRO	0	Not reported	06/01/2026	06/05/2026
Flynn Brian	COMPRA	+4,012	Not reported	05/26/2026	05/28/2026
Duchemin-Leslie Nadine	COMPRA	+4,012	Not reported	05/26/2026	05/28/2026
Pugliese John	COMPRA	+4,012	Not reported	05/26/2026	05/28/2026
Hanson James E. II	COMPRA	+4,012	Not reported	05/26/2026	05/28/2026
Gragnolati Brian	COMPRA	+4,012	Not reported	05/26/2026	05/28/2026
Harding Matthew K.	COMPRA	+4,012	Not reported	05/26/2026	05/28/2026
Foley Ursuline F	COMPRA	+4,012	Not reported	05/26/2026	05/28/2026
MCCRACKEN ROBERT E	COMPRA	+4,012	Not reported	05/26/2026	05/28/2026
SHARA THOMAS	COMPRA	+4,012	Not reported	05/26/2026	05/28/2026
LEPPERT EDWARD J	COMPRA	+4,012	Not reported	05/26/2026	05/28/2026
LABOZZETTA ANTHONY J	VENTA	-10,416	$22.15	05/20/2026	05/22/2026
Giannola Vito	VENTA	-1,626	$22.15	05/20/2026	05/21/2026
Duarte Adriano M.	VENTA	-2,071	$22.15	05/20/2026	05/21/2026
Vakacherla Ravi	VENTA	-2,760	$22.15	05/20/2026	05/21/2026
LYONS THOMAS M	COMPRA	+10,883	Not reported	05/20/2026	05/21/2026
Christy James A.	VENTA	-1,144	$22.15	05/20/2026	05/21/2026
MacDougall Bennett	VENTA	-2,712	$22.15	05/20/2026	05/21/2026
Powell Carolyn	VENTA	-2,178	$22.15	05/20/2026	05/21/2026

Sobre la compañía

Provident Financial Services, Inc.

Provident Financial Services, Inc. functions as the parent company for Provident Bank, delivering a broad spectrum of financial products and services to individuals, families, and businesses across the United States. Its deposit offerings encompass various account types, including savings, standard and interest-bearing checking accounts, money market accounts, certificates of deposit, and IRA products. The company's extensive loan portfolio features commercial real estate loans, which are collateralized by properties such as multi-family apartment complexes, office buildings, retail spaces, and industrial sites. It also provides commercial business loans, alongside fixed-rate and adjustable-rate mortgage loans secured by one-to-four family residential properties. Further loan options include commercial construction loans and a range of consumer loans like home equity loans, home equity lines of credit, marine loans, personal loans and unsecured lines of credit, and financing for automobiles and recreational vehicles. Beyond these, Provident delivers essential banking solutions such as cash management, remote deposit capture, payroll origination, escrow account management, and convenient online and mobile banking services, in addition to offering business credit cards. The company also extends wealth management services, covering investment management, trust and estate administration, financial planning, tax compliance and planning, and private banking. In a broader capacity, Provident sells insurance and investment products, including annuities. It also operates as a real estate investment trust (REIT), focused on acquiring mortgage loans and other real estate-related assets, and actively manages and sells properties obtained through foreclosure. As of December 31, 2021, the company maintained 96 full-service branch offices situated across northern and central New Jersey, as well as specific counties in Pennsylvania and New York. Provident Financial Services, Inc. was founded in 1839 and is headquartered in Jersey City, New Jersey.

Fuente - Link

Competidores

BANR CVBF FFBC NBTB PRK SFNC TOWN TRMK WAFD WAL

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:01 allele status or line of therapy OptimUM-01 data demonstrates encouraging clinical activity from darovasertib combined with crizotinib in both treatment-naïve (7.4 month PFS, 27.1 month mOS, n=13) and heavily pretreated HLA-A*02:01-positive metastatic uveal melanoma, including in 2L patients following tebentafusp Treatment-naïve patients in OptimUM-01 and OptimUM-02 demonstrate comparable ORR, PFS and DOR in HLA-A*02:01-positive and -negative patients and consistent improvements in ORR and PFS versus investigator's choice of therapy across a range of clinically relevant subgroups OptimUM-09 continues to demonstrate robust tumor shrinkage in >80% of primary uveal melanoma patients treated with neoadjuvant darovasertib, resulting in a 57% eye preservation rate and 66% of patients achieving a reduced projected dose of radiation to critical eye structures in the enucleation and plaque brachytherapy cohorts, respectively SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and primary uveal melanoma (UM) that will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place on October 23–27 in Madrid, Spain.

PRNewsWire

/C O R R E C T I O N - AbbVie/

/C O R R E C T I O N - AbbVie/PR NewswireNORTH CHICAGO, Ill., Oct. 18, 2026In the news release, AbbVie to Present Data at the 2026 European Society for Medical

GuruFocus

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioPR News

GuruFocus

Bristol Myers Squibb (BMY) Gains on Positive Phase 3 Results for RYZ101 and Admilparant

Bristol Myers Squibb (BMY) shares are rising following encouraging Phase 3 results for RYZ101 and admilparant, which present two promising growth avenues as the

GuruFocus

Provident Financial Services (NYSE:PFS) & F.N.B. (NYSE:FNB) Financial Review

F.N.B. (NYSE: FNB - Get Free Report) and Provident Financial Services (NYSE: PFS - Get Free Report) are both mid-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations. Analyst Recommendations This is a summary of

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-29	0.55	0.61	0.06
2026-01-27	0.56	0.64	0.08
2025-10-29	0.543	0.55	0.007
2025-07-24	0.4962	0.55	0.0538
2025-04-24	0.472	0.5	0.028
2025-01-28	0.5	0.37	-0.13
2024-10-29	0.47	0.36	-0.11
2024-07-25	0.4275	0.06	-0.3675
2024-04-18	0.4	0.43	0.03
2024-01-25	0.4	0.44	0.04
2023-10-26	0.38	0.41	0.03
2023-07-27	0.44	0.43	-0.01